维生素D3对脓毒症患者病情严重程度及预后的影响:一项前瞻性随机双盲安慰剂研究
该前瞻性随机双盲安慰剂研究纳入2015年3月至11月中国医科大学附属盛京医院ICU收治的57例脓毒症患者,另设20例全身炎症反应综合征(SIRS)患者和20例健康志愿者为对照。脓毒症患者按2012年严重脓毒症和脓毒性休克诊断标准分为一般脓毒症组(15例)和严重脓毒症组(42例);根据美国内分泌学会诊断标准及25(OH)D3水平,将维生素D缺乏[25(OH)D3 20-30 μg/L]或不足[25(OH)D3 < 20 μg/L]的脓毒症患者分为D3治疗组(补充300 kU维生素D3,29例)和安慰剂组(注射1 mL生理盐水,28例),以第28天为终点。结果显示,脓毒症组和SIRS组血清25(OH)D3均显著低于健康对照组,但脓毒症组与SIRS组间无显著差异;女性脓毒症患者25(OH)D3显著低于男性;D3治疗组与安慰剂组在机械通气时长、ICU住院天数及28天死亡率方面均无显著差异。多因素Cox回归分析显示APACHE II评分和25(OH)D3 < 20 μg/L是脓毒症预后的危险因素。
要点
- 脓毒症患者血清25(OH)D3水平显著低于健康对照[μg/L:3.92(<3.00,11.22)vs. 17.25(13.48,22.50),P < 0.01],但与SIRS组无显著差异。
- 女性脓毒症患者25(OH)D3显著低于男性[μg/L:<3.00(<3.00,3.87)vs. 11.96(5.14,17.29),Z = -4.020,P = 0.000]。
- 补充300 kU维生素D3与安慰剂相比,28天死亡率(10.34% vs. 17.86%)、机械通气时长及ICU住院天数均无显著差异(均P > 0.05)。
- 多因素Cox回归显示APACHE II评分(RR = 8.487,95%CI 1.506-47.835,P = 0.015)和25(OH)D3 < 20 μg/L(RR = 0.088,95%CI 0.013-0.592,P = 0.012)是脓毒症预后的危险因素。
适用人群与场景
- 2015年3月至11月中国医科大学附属盛京医院ICU收治的脓毒症患者57例,其中一般脓毒症15例、严重脓毒症(含脓毒性休克)42例。
- 同期纳入20例全身炎症反应综合征(SIRS)患者和20例体检正常的健康志愿者作为对照。
- 脓毒症患者中按美国内分泌学会诊断标准及25(OH)D3水平分为D3治疗组29例和安慰剂组28例。
诊断标准与关键阈值
- 脓毒症分组依据2012年严重脓毒症和脓毒性休克诊断标准,分为一般脓毒症组和严重脓毒症组(含脓毒性休克)。
- 维生素D缺乏或不足依据美国内分泌学会诊断标准及25(OH)D3水平:缺乏为25(OH)D3 20-30 μg/L,不足为25(OH)D3 < 20 μg/L。
处置流程与药物剂量
- D3治疗组补充300 kU维生素D3,安慰剂组注射1 mL生理盐水;原文未写明给药途径及频次。
- 以第28天为终点,观察血清25(OH)D3、降钙素原、C反应蛋白、血常规、肝肾功能、电解质、动脉血气分析、APACHE II评分、SOFA评分、机械通气时长及ICU住院天数。
研究设计与关键结果
- 研究类型为前瞻性随机双盲安慰剂研究,纳入57例脓毒症患者、20例SIRS患者和20例健康对照。
- 脓毒症组和SIRS组血清25(OH)D3均显著低于健康对照组[μg/L:3.92(<3.00,11.22)、6.99(3.51,9.77)vs. 17.25(13.48,22.50),均P < 0.01],但脓毒症组与SIRS组间无显著差异。
- 脓毒症组内不同严重程度患者间血清25(OH)D3水平无显著差异。
- 女性脓毒症患者(n = 24)血清25(OH)D3显著低于男性(n = 33)[μg/L:<3.00(<3.00,3.87)vs. 11.96(5.14,17.29),Z = -4.020,P = 0.000]。
- 年轻(<60岁,n = 30)与老年(≥60岁,n = 27)脓毒症患者血清25(OH)D3水平无显著差异[μg/L:4.54(<3.00,9.88)vs. 3.00(<3.00,15.08),Z = -0.601,P = 0.548]。
- D3治疗组与安慰剂组机械通气时长[小时:41.00(7.50,82.50)vs. 67.00(4.75,127.75)]、ICU住院天数(天:5.48±4.08 vs. 6.68±4.87)及28天死亡率(10.34% vs. 17.86%)均无显著差异(均P > 0.05)。
- Kaplan-Meier生存曲线分析显示两组28天累积生存率无显著差异(log-rank检验:χ² = 0.222,P = 0.638)。
- 多因素Cox回归分析显示APACHE II评分(RR = 8.487,95%CI 1.506-47.835,P = 0.015)和25(OH)D3 < 20 μg/L(RR = 0.088,95%CI 0.013-0.592,P = 0.012)是脓毒症预后的危险因素。
证据类型、等级与局限
- 证据类型为前瞻性随机双盲安慰剂研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于ICU脓毒症患者,补充300 kU维生素D3未能改善28天死亡率、机械通气时长及ICU住院天数。
- 女性脓毒症患者血清25(OH)D3水平低于男性,但年龄与25(OH)D3水平无关。
- APACHE II评分和25(OH)D3 < 20 μg/L是ICU脓毒症患者预后的危险因素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To observe the relationship between vitamin D3 and the severity as well as prognosis in patients with sepsis, and to explore whether exogenous vitamin D3 can improve the prognosis in patients with sepsis.
METHODS: A prospective randomized double-blind placebo study was conducted. Fifty-seven patients with sepsis admitted to intensive care unit (ICU) of Shengjing Hospital Affiliated to China Medical University from March to November in 2015 were enrolled. Twenty patients with systemic inflammatory response syndrome (SIRS) and 20 healthy volunteers with normal physical examination as control were enrolled during the same time. Patients with sepsis were divided into general sepsis group and severe sepsis group (including septic shock) according to the criteria for the diagnosis of severe sepsis and septic shock in 2012. According to the diagnostic criteria established by the American Endocrine Society, and on the basis of 25-hydroxy vitamin D3 [25(OH)D3], the sepsis patients with deficiency [25(OH)D3 20-30 μg/L] or insufficiency [25(OH)D3 < 20 μg/L] of vitamin D were divided into D3 treatment group (supplemented 300 kU vitamin D3) and placebo group (injected 1 mL physiological saline). 28th day was set as the end point, and the patients with sepsis were divided into survival group and death group. The levels of serum 25(OH)D3 in each group were measured by electrochemical luminescence method, and the difference in 25(OH)D3 levels among patients with different severity, gender, and age were recorded. Procalcitonin (PCT), C-reactive protein (CRP), blood routine, liver and kidney function, electrolytes and arterial blood gas analysis, acute physiology and chronic health evaluation II (APACHE II) and sequential organ failure score (SOFA), duration of mechanical ventilation, and length of ICU stay of patients with sepsis were observed. Multivariate Cox proportional hazard regression analysis was used to analyze the risk factors of prognosis in patients with sepsis.
RESULTS: (1) In 57 patients with sepsis, there were 15 patients in general sepsis group, and 42 in severe sepsis group; 29 in D3 treatment group, and 28 in the placebo group; 8 patients died within 28 days with mortality rate of 14.04%. (2) The levels of serum 25(OH)D3 in sepsis group and SIRS group were significantly lower than those in healthy control group [μg/L: 3.92 (< 3.00, 11.22), 6.99 (3.51, 9.77) vs. 17.25 (13.48, 22.50), both P < 0.01], but there was no significant difference in the serum 25(OH)D3 level between sepsis group and SIRS group as well as patients with different degrees of sepsis. The serum 25(OH)D3 level in female patients with sepsis (n = 24) was significantly lower than that in male (n = 33), and the difference was statistically significant [μg/L: <3.00 (<3.00, 3.87) vs. 11.96 (5.14, 17.29), Z = -4.020, P = 0.000]. There was no significant difference in serum 25(OH)D3 level between the young (age <60 years old, n = 30) and the old (age ≥ 60 years old, n = 27) patients with sepsis [μg/L: 4.54 (<3.00, 9.88) vs. 3.00 (<3.00, 15.08), Z = -0.601, P = 0.548]. (3) In patients with sepsis, there was no significant difference in the duration of mechanical ventilation [hours: 41.00 (7.50, 82.50) vs. 67.00 (4.75, 127.75)], length of ICU stay (days: 5.48±4.08 vs. 6.68±4.87) and 28-day mortality (10.34% vs. 17.86%) between D3 treatment group and placebo group (all P > 0.05). It was shown by Kaplan-Meier survival curve analysis that there was no significance in 28-day accumulated survived rate between the two groups [log-rank test: χ 2 = 0.222, P = 0.638]. It was shown by multivariate Cox regression analysis that APACHE II score [relative risk (RR) = 8.487, 95% confidence interval (95%CI) = 1.506-47.835, P = 0.015] and 25(OH)D3 < 20 μg/L (RR = 0.088, 95%CI = 0.013-0.592, P = 0.012) were the risk factors of prognosis in patients with sepsis.
CONCLUSIONS: The serum 25(OH)D3 level in ICU patients with sepsis was lower than that in healthy people, but there was no significant difference between patients with sepsis and SIRS. The serum 25(OH)D3 level in sepsis patients was related with gender, and the level of the female was lower than that of the male, but was not related with age. Exogenous vitamin D3 supplementation cannot improve the prognosis of ICU patients with sepsis. APACHE II score and 25(OH)D3 < 20 μg/L were risk factors for the prognosis in ICU patients with sepsis.
参考来源
- Ding F, Zang B, Fu J, et al. [Effect of vitamin D3 on the severity and prognosis of patients with sepsis: a prospective randomized double-blind placebo study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28625255. doi:10.3760/cma.j.issn.2095-4352.2017.02.003
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。